A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings

Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device.

The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors. In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc.

“We are extremely pleased to close this round of financing with strong support from our investors, validating the clear unmet need for a treatment that safely and efficiently achieves high intraocular pressure (IOP) reduction for moderate to severe glaucoma patients.” stated Robert Chang, CEO of Myra Vision. “Myra Vision’s innovative nanotechnology device is designed to allow physicians to safely maximize outflow to achieve optimized IOP reduction.”

Glaucoma, a leading cause of blindness, affects an estimated 66M people worldwide. More than one third of patients have moderate to severe glaucoma, which requires significant reductions in IOP. Traditionally, these patients have been treated with glaucoma surgery, including trabeculectomy and tube shunt implants. Recent advances in minimally invasive glaucoma surgery (MIGS) devices offer simpler and safer surgical treatment options. While the current MIGS devices have demonstrated an improvement in complication rates, they are not able to achieve the IOP reductions necessary for the moderate to severe glaucoma patient population.

“We are pleased to lead this round and believe Myra Vision’s next-generation technology has the potential to deliver a much-needed treatment for this large and underserved segment of the glaucoma market,” commented Casey Gordon, Head of Private Investments at TCP. “With Myra’s solution, physicians can personalize outflow depending on each patient’s evolving needs. We believe this will revolutionize care by vastly improving patient outcomes and satisfaction.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy